Dupilumab for the Treatment of Severe Atopic Dermatitis in an Immunosuppressed Transplant Patient
- 10 August 2023
- journal article
- research article
- Published by SAGE Publications in Dermatitis®
- Vol. 35 (1_suppl) , S109-S110
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with DupilumabAdvances in Therapy, 2022
- ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and childrenJournal of the European Academy of Dermatology and Venereology, 2020
- Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension studyJournal of the American Academy of Dermatology, 2020
- Bacterial and Viral Infections in Atopic Dermatitis: a Comprehensive ReviewClinical Reviews in Allergy & Immunology, 2016